Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd has announced July 16, 2026, as the record date for its upcoming bonus equity share issue. The Board of Directors has approved a bonus ratio of 2:1, meaning shareholders will receive two fully paid-up equity shares of ₹10 each for every one existing equity share held. This issuance was previously approved by shareholders at the Annual General Meeting on June 30, 2026. The deemed date of allotment for these bonus shares will be the next working day following the record date (T+1). The new shares will rank pari passu with existing shares. Arrangements have also been made to adjust outstanding warrants to ensure holders receive equivalent economic benefits.

Fredun Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from Wednesday, July 1st, 2026, until 48 hours after the board meeting where the unaudited financial results for the quarter ended June 30th, 2026, will be considered, approved, and declared. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Fredun Pharmaceuticals Ltd has announced that its 39th Annual General Meeting (AGM) will be held on Tuesday, June 30, 2026, at 9:00 am IST via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The company is sending letters to members without registered email addresses, providing a weblink to access the Annual Report for FY 2025-26 and the AGM notice. This communication also serves as a reminder for shareholders holding physical securities to update their KYC details as per SEBI's latest circular, including PAN, address, mobile number, bank details, and nomination choice, to ensure continued eligibility for payments like dividends.

Fredun Pharmaceuticals Limited has announced the book closure dates for its 39th Annual General Meeting (AGM). The AGM will be held on Tuesday, June 30, 2026, via Video Conference (VC) or Other Audio Visual Means (OAVM). In accordance with Section 91 of the Companies Act, 2013, and SEBI regulations, the company's Register of Members and Share Transfer Books will be closed from Wednesday, June 24, 2026, to Tuesday, June 30, 2026, inclusive. This closure is to facilitate the AGM proceedings.

Fredun Pharmaceuticals Ltd has announced the record date for its final dividend for the Financial Year 2025-26. The record date is set for Tuesday, June 23, 2026. The company proposes a final dividend of 7% on equity shares with a face value of Rs. 10 each. If approved by shareholders at the upcoming Annual General Meeting, the dividend payment will be processed within 30 days of approval, subject to tax deductions.

Fredun Pharmaceuticals Ltd has filed its Annual Report for the Financial Year 2025-2026 and the Notice for its 39th Annual General Meeting (AGM). The AGM is scheduled for Tuesday, June 30, 2026, at 9:00 AM and will be conducted via Video Conference (VC) / Other Audio Visual Means (OAVM). The Annual Report is also available on the company's website, www.fredungroup.com. The filing includes sections on corporate information, directors' report, financial statements, auditor's report, and corporate governance.

Fredun Pharmaceuticals Limited has issued a notice for its 39th Annual General Meeting (AGM), scheduled for Tuesday, June 30, 2026, at 09:00 a.m. The meeting will be conducted via Video Conference (VC) / Other Audio Visual Means (OAVM). The company has also uploaded its Annual Report for the Financial Year 2025-2026, which includes the AGM notice, on its website. The report contains various sections including financial statements, directors' report, and corporate governance information.

Fredun Pharmaceuticals Ltd re-appointed M/s. Nikhil Maniar & Associates as Internal Auditor and M/s. Joshi Apte & Associates as Cost Auditor for the financial year 2026-2027. This decision was made during the Board of Directors meeting held on May 25, 2026, where the board also approved the audited financial results for the quarter and financial year ended March 31, 2026, recommended a final dividend of 7% (₹0.70 per share), approved an increase in authorized share capital, and approved the issuance of bonus shares in the ratio of 2:1.

Fredun Pharmaceuticals Ltd's board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. They recommended a final dividend of 7% (70 paise per share). The board also approved an increase in authorized share capital from ₹10 Crores to ₹50 Crores and a bonus share issue in the ratio of 2:1, subject to shareholder approval. Additionally, M/s. Nikhil Maniar & Associates and M/s. Joshi Apte & Associates were appointed as Internal Auditor and Cost Auditor, respectively, for FY 2026-27.

Fredun Pharmaceuticals Ltd reported robust FY26 results with revenue jumping 40% to ₹639 Cr, EBITDA surging 72% to ₹94.79 Cr, and profit rising ~60% to ₹33.21 Cr YoY. The company's performance reflects growth across generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare products. The Board recommended a dividend of ₹0.70 per share and a bonus share issuance in the ratio of 2:1. Fredun is expanding its Palghar facility and has received a credit rating upgrade to IVR BBB+.